RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
TCMGX
Price
$19.30
Change
-$0.14 (-0.72%)
Updated
Sep 20 closing price
Ad is loading...

RPTIX vs TCMGX

Header iconRPTIX vs TCMGX Comparison
Open Charts RPTIX vs TCMGXBanner chart's image
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
Nuveen Mid Cap Growth A
Price$19.30
Change-$0.14 (-0.72%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
RPTIX vs TCMGX Comparison Chart
Loading...
VS
RPTIX vs. TCMGX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPTIX is a StrongBuy and TCMGX is a Buy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. TCMGX (957M). RPTIX pays higher dividends than TCMGX: RPTIX (0.18) vs TCMGX (0.00). RPTIX was incepted earlier than TCMGX: RPTIX (9 years) vs TCMGX (22 years). TCMGX is a more actively managed with annual turnover of: 38.00 vs. RPTIX (21.70). TCMGX has a lower initial minimum investment than RPTIX: TCMGX (2500) vs RPTIX (500000). TCMGX annual gain was more profitable for investors over the last year : 15.58 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. TCMGX (-10.70).
RPTIXTCMGXRPTIX / TCMGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years22 years-
Gain YTD9.1273.625252%
Front LoadN/AN/A-
Min. Initial Investment500000250020,000%
Min. Initial Investment IRAN/AN/A-
Net Assets31.4B957M3,281%
Annual Yield % from dividends0.180.00-
Returns for 1 year14.8115.5895%
Returns for 3 years-13.57-32.9041%
Returns for 5 years15.09-10.70-141%
Returns for 10 yearsN/A-16.46-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp